No Data
LIVZON PHARMA (01513.HK) spent 5.238 million Hong Kong dollars to buy back 0.195 million shares on December 20.
On December 20, Glonhui reported that LIVZON PHARMA (01513.HK) announced it repurchased 195,000 shares for HKD 5.238 million.
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
LIVZON PHARMA (01513.HK) spent HKD 2.712 million to repurchase 0.1 million shares on December 19.
Gelonghui reported on December 19 that LIVZON PHARMA (01513.HK) announced the repurchase of 100,000 shares at a cost of 2.712 million Hong Kong dollars on December 19.
Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?
On December 18, LIVZON PHARMA (01513) spent HKD 2.6035 million to buy back 0.0965 million shares.
LIVZON PHARMA (01513) announced that it will spend 2.6035 million Hong Kong dollars to repurchase on December 18, 2024...
On December 17, LIVZON PHARMA (01513) spent approximately 5.2979 million Hong Kong dollars to repurchase 0.1964 million shares.
LIVZON PHARMA (01513) announced that on December 17, 2024, approximately 5.2979 million Hong Kong dollars were spent to repurchase 19...
The Market Doesn't Like What It Sees From Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Earnings Yet
No Data
